Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
2006; Elsevier BV; Volume: 42; Issue: 10 Linguagem: Inglês
10.1016/j.ejca.2006.02.011
ISSN1879-0852
AutoresLaurence Collette, Tomasz Burzykowski, Fritz H. Schröder,
Tópico(s)Prostate Cancer Treatment and Research
Referência(s)